Literature DB >> 12680543

Anti-tuberculous drug prescribing: doctors' compliance at a private teaching hospital in Pakistan.

Javaid A Khan1, S Fayyaz Hussain.   

Abstract

An adequate and appropriate anti-TB drug prescription is of crucial importance in order to "cure" a TB patient of his or her disease. This study looked at the prescribing habits of doctors working in a private teaching hospital of Pakistan. The results showed that the majority of doctors (79%) were choosing the correct four-drug regiment of RHZE in the intensive phase, as recommended in the National Guidelines. However, the dosage of some drugs were below the recommended ranges (43% of prescriptions for Pyraizinamide and 48% for Ethambutol). Regular audit of doctors' prescriptions is necessary in order to ensure that the National TB Guidelines are fully implemented by physicians working in the private sector of Pakistan.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680543     DOI: 10.1177/004947550303300213

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  4 in total

1.  Comprehensiveness of primary services in the care of infectious tuberculosis patients in Rawalpindi, Pakistan.

Authors:  R Fatima; Q Ejaz; D A Enarson; K Bissell
Journal:  Public Health Action       Date:  2011-09-21

Review 2.  Knowledge of tuberculosis-treatment prescription of health workers: a systematic review.

Authors:  Marieke J van der Werf; Miranda W Langendam; Emma Huitric; Davide Manissero
Journal:  Eur Respir J       Date:  2011-12-19       Impact factor: 16.671

Review 3.  Prevalence of inappropriate tuberculosis treatment regimens: a systematic review.

Authors:  M W Langendam; M J van der Werf; E Huitric; D Manissero
Journal:  Eur Respir J       Date:  2011-10-17       Impact factor: 16.671

4.  Management of tuberculosis by healthcare practitioners in Pakistan: A systematic review.

Authors:  Christy A Braham; Peter J White; Nimalan Arinaminpathy
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.